These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21572247)

  • 1. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.
    Inagaki Y; Qi F; Gao J; Qu X; Hasegawa K; Sugawara Y; Tang W; Kokudo N
    Biosci Trends; 2011; 5(2):52-6. PubMed ID: 21572247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
    Kenessey I; Keszthelyi M; Krámer Z; Berta J; Adám A; Dobos J; Mildner M; Flachner B; Cseh S; Barna G; Szokol B; Orfi L; Kéri G; Döme B; Klepetko W; Tímár J; Tóvári J
    Curr Cancer Drug Targets; 2010 May; 10(3):332-42. PubMed ID: 20370683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
    Gao W; Bing X; Li M; Yang Z; Li Y; Chen H
    Med Oncol; 2013 Jun; 30(2):546. PubMed ID: 23536000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.
    Gao J; Inagaki Y; Song P; Qu X; Kokudo N; Tang W
    Pharmacol Res; 2012 Jan; 65(1):23-30. PubMed ID: 22138044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
    Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
    J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
    Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
    J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
    Steinway SN; Dang H; You H; Rountree CB; Ding W
    PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
    You H; Ding W; Dang H; Jiang Y; Rountree CB
    Hepatology; 2011 Sep; 54(3):879-89. PubMed ID: 21618573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
    Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
    Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma.
    Cui SX; Yu XF; Qu XJ
    Cancer Invest; 2016 Oct; 34(9):459-464. PubMed ID: 27673353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
    Front Immunol; 2021; 12():731527. PubMed ID: 34804015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway.
    Yue P; Gao ZH; Xue X; Cui SX; Zhao CR; Yuan Y; Yin Z; Inagaki Y; Kokudo N; Tang W; Qu XJ
    Eur J Cancer; 2011 May; 47(7):1115-24. PubMed ID: 21349701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
    Cui SX; Zhang YS; Chu JH; Song ZY; Qu XJ
    Cell Physiol Biochem; 2015; 35(1):201-12. PubMed ID: 25591763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.
    Cheng J; Wu LM; Deng XS; Wu J; Lv Z; Zhao HF; Yang Z; Ni Y
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):336-344. PubMed ID: 30108016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
    Gao J; Jia WD; Li JS; Wang W; Xu GL; Ma JL; Ge YS; Yu JH; Ren WH; Liu WB; Zhang CH
    J Int Med Res; 2010; 38(4):1413-27. PubMed ID: 20926014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.
    Yu Z; Zhao R
    Anticancer Drugs; 2018 Jul; 29(6):513-519. PubMed ID: 29570100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.